表紙
市場調査レポート

HIV/AIDS:パイプライン分析

HIV / AIDS - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 232769
出版日 ページ情報 英文 916 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
HIV/AIDS:パイプライン分析 HIV / AIDS - Pipeline Review, H2 2015
出版日: 2015年12月31日 ページ情報: 英文 916 Pages
概要

HIV とは、免疫システムを攻撃するウィルスのことで、感染症や疾患と戦う体内の力を弱めてしまいます。症状は熱、のどの痛み、体中の発疹、関節痛、筋肉痛、腺の肥大などが見られます。HIVの感染が一番拡大しやすいのは、HIV/AIDS感染者との避妊具を使わない性交や、感染者と注射針を共有したり、HIVのついた外科用器具で体に深い傷がついたり、HIVに感染している血液、体液などが開いた傷口などから入ってくることなどです。

当レポートでは、HIV / AIDS の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

HIV / AIDS 概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7061IDB

Summary

Global Markets Direct's, 'HIV / AIDS - Pipeline Review, H2 2015', provides an overview of the HIV / AIDS's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for HIV / AIDS, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDS and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of HIV / AIDS
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for HIV / AIDS and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the HIV / AIDS products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the HIV / AIDS pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for HIV / AIDS
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • HIV / AIDS Overview
  • Therapeutics Development
  • HIV / AIDS - Therapeutics under Development by Companies
  • HIV / AIDS - Therapeutics under Investigation by Universities/Institutes
  • HIV / AIDS - Pipeline Products Glance
  • HIV / AIDS - Products under Development by Companies
  • HIV / AIDS - Products under Investigation by Universities/Institutes
  • HIV / AIDS - Companies Involved in Therapeutics Development
  • HIV / AIDS - Therapeutics Assessment
  • Drug Profiles
  • HIV / AIDS - Recent Pipeline Updates
  • HIV / AIDS - Dormant Projects
  • HIV / AIDS - Discontinued Products
  • HIV / AIDS - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for HIV / AIDS, H2 2015
  • Number of Products under Development for HIV / AIDS - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Development by Companies, H2 2015 (Contd..5)
  • Number of Products under Development by Companies, H2 2015 (Contd..6)
  • Number of Products under Development by Companies, H2 2015 (Contd..7)
  • Number of Products under Development by Companies, H2 2015 (Contd..8)
  • Number of Products under Development by Companies, H2 2015 (Contd..9)
  • Number of Products under Development by Companies, H2 2015 (Contd..10)
  • Number of Products under Development by Companies, H2 2015 (Contd..11)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Development by Companies, H2 2015 (Contd..9)
  • Products under Development by Companies, H2 2015 (Contd..10)
  • Products under Development by Companies, H2 2015 (Contd..11)
  • Products under Development by Companies, H2 2015 (Contd..12)
  • Products under Development by Companies, H2 2015 (Contd..13)
  • Products under Development by Companies, H2 2015 (Contd..14)
  • Products under Development by Companies, H2 2015 (Contd..15)
  • Products under Development by Companies, H2 2015 (Contd..16)
  • Products under Development by Companies, H2 2015 (Contd..17)
  • Products under Development by Companies, H2 2015 (Contd..18)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..8)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..9)
  • HIV / AIDS - Pipeline by Abivax S.A., H2 2015
  • HIV / AIDS - Pipeline by Adaptimmune Limited, H2 2015
  • HIV / AIDS - Pipeline by AiCuris GmbH & Co. KG, H2 2015
  • HIV / AIDS - Pipeline by Akshaya Bio Inc., H2 2015
  • HIV / AIDS - Pipeline by Altor BioScience Corporation, H2 2015
  • HIV / AIDS - Pipeline by AltraVax Inc., H2 2015
  • HIV / AIDS - Pipeline by Amarna Therapeutics B.V., H2 2015
  • HIV / AIDS - Pipeline by American Gene Technologies International Inc., H2 2015
  • HIV / AIDS - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2015
  • HIV / AIDS - Pipeline by Antigen Express, Inc., H2 2015
  • HIV / AIDS - Pipeline by Aphios Corporation, H2 2015
  • HIV / AIDS - Pipeline by Apotex, Inc., H2 2015
  • HIV / AIDS - Pipeline by Argos Therapeutics, Inc., H2 2015
  • HIV / AIDS - Pipeline by Arno Therapeutics, Inc., H2 2015
  • HIV / AIDS - Pipeline by Avexa Limited, H2 2015
  • HIV / AIDS - Pipeline by BCI Pharma, H2 2015
  • HIV / AIDS - Pipeline by Beth Israel Deaconess Medical Center, Inc., H2 2015
  • HIV / AIDS - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2015
  • HIV / AIDS - Pipeline by Bionor Pharma ASA, H2 2015
  • HIV / AIDS - Pipeline by Biosantech SA, H2 2015
  • HIV / AIDS - Pipeline by BioSource Pharm, Inc., H2 2015
  • HIV / AIDS - Pipeline by Biotron Limited, H2 2015
  • HIV / AIDS - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • HIV / AIDS - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • HIV / AIDS - Pipeline by C4X Discovery Limited, H2 2015
  • HIV / AIDS - Pipeline by Calimmune, Inc., H2 2015
  • HIV / AIDS - Pipeline by Celldex Therapeutics, Inc., H2 2015
  • HIV / AIDS - Pipeline by Chipscreen Biosciences Ltd, H2 2015
  • HIV / AIDS - Pipeline by Cocrystal Pharma, Inc., H2 2015
  • HIV / AIDS - Pipeline by CompleGen, Inc., H2 2015
  • HIV / AIDS - Pipeline by Critical Outcome Technologies Inc., H2 2015
  • HIV / AIDS - Pipeline by CureVac GmbH, H2 2015
  • HIV / AIDS - Pipeline by Cytodyn Inc., H2 2015
  • HIV / AIDS - Pipeline by DNAVEC Corporation, H2 2015
  • HIV / AIDS - Pipeline by Dong-A ST Co., Ltd., H2 2015
  • HIV / AIDS - Pipeline by Enzo Biochem, Inc., H2 2015
  • HIV / AIDS - Pipeline by EpiVax, Inc., H2 2015
  • HIV / AIDS - Pipeline by Etubics Corporation, H2 2015
  • HIV / AIDS - Pipeline by Evofem, Inc., H2 2015
  • HIV / AIDS - Pipeline by FIT Biotech Oy, H2 2015
  • HIV / AIDS - Pipeline by Formune S.L., H2 2015
  • HIV / AIDS - Pipeline by Fountain Biopharma Inc., H2 2015
  • HIV / AIDS - Pipeline by Frontier Biotechnologies Co., Ltd, H2 2015
  • HIV / AIDS - Pipeline by GeneCure LLC, H2 2015
  • HIV / AIDS - Pipeline by Genetic Immunity, Inc, H2 2015
  • HIV / AIDS - Pipeline by Genticel S.A., H2 2015
  • HIV / AIDS - Pipeline by GeoVax Labs, Inc., H2 2015
  • HIV / AIDS - Pipeline by Gilead Sciences, Inc., H2 2015
  • HIV / AIDS - Pipeline by GlaxoSmithKline Plc, H2 2015
  • HIV / AIDS - Pipeline by Globeimmune, Inc., H2 2015
  • HIV / AIDS - Pipeline by H-Phar S.A., H2 2015
  • HIV / AIDS - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015
  • HIV / AIDS - Pipeline by Heat Biologics, Inc., H2 2015
  • HIV / AIDS - Pipeline by Heptares Therapeutics Limited, H2 2015
  • HIV / AIDS - Pipeline by Humabs BioMed SA, H2 2015
  • HIV / AIDS - Pipeline by iCo Therapeutics Inc., H2 2015
  • HIV / AIDS - Pipeline by Immune Response BioPharma, Inc., H2 2015
  • HIV / AIDS - Pipeline by Immunocore Limited, H2 2015
  • HIV / AIDS - Pipeline by Immunomic Therapeutics, Inc., H2 2015
  • HIV / AIDS - Pipeline by Immuron Limited, H2 2015
  • HIV / AIDS - Pipeline by ImQuest Life Sciences, H2 2015
  • HIV / AIDS - Pipeline by InnaVirVax SA, H2 2015
  • HIV / AIDS - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
  • HIV / AIDS - Pipeline by Japan Tobacco Inc., H2 2015
  • HIV / AIDS - Pipeline by Johnson & Johnson, H2 2015
  • HIV / AIDS - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
  • HIV / AIDS - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
  • HIV / AIDS - Pipeline by Kineta, Inc., H2 2015
  • HIV / AIDS - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2015
  • HIV / AIDS - Pipeline by Longevity Biotech, Inc, H2 2015
  • HIV / AIDS - Pipeline by MacroGenics, Inc., H2 2015
  • HIV / AIDS - Pipeline by Medestea Research & Production S.p.A., H2 2015
  • HIV / AIDS - Pipeline by Medivir AB, H2 2015
  • HIV / AIDS - Pipeline by Merck & Co., Inc., H2 2015
  • HIV / AIDS - Pipeline by Mologen AG, H2 2015
  • HIV / AIDS - Pipeline by Mymetics Corporation, H2 2015
  • HIV / AIDS - Pipeline by Myrexis, Inc., H2 2015

List of Figures

  • Number of Products under Development for HIV / AIDS, H2 2015
  • Number of Products under Development for HIV / AIDS - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top